Asma Amir Ali1, Elizabeth K Seng2, Afsaneh Alavi3, Michelle A Lowes4. 1. Schulich School of Medicine & Dentistry, Western University, London, Ontario, Canada. 2. Ferkauf Graduate School of Psychology, Yeshiva University, Bronx, New York; Saul R. Korey Department of Neurology, Albert Einstein College of Medicine, Bronx, New York. 3. Division of Dermatology, Department of Medicine, Women's College Hospital, University of Toronto, Toronto, Ontario, Canada. 4. The Rockefeller University, New York, New York. Electronic address: lowesm@rockefeller.edu.
Abstract
BACKGROUND: Hidradenitis suppurativa (HS) is characterized by recurrent, painful nodules in flexural areas. OBJECTIVE: The objective of this study was to explore the placebo response in HS randomized clinical trials and to compare it briefly with the placebo response in psoriasis and atopic dermatitis. METHODS: A Cochrane Review on interventions in HS was used as a starting point, and a systematic review was then undertaken by using the PubMed database, yielding 7 HS randomized clinical trials for inclusion in this study. RESULTS: This review demonstrates that there is a robust placebo response in HS that is most marked in physical signs but also marked in pain responses. LIMITATIONS: Multiple outcome measures utilized in these studies and reporting bias limited this review. CONCLUSION: This large placebo response has implications for clinical trial design. This knowledge can also help deliver improved clinical care by forming the basis of nonpharmacologic treatments and help optimize current medication use to maximize the placebo effect.
BACKGROUND:Hidradenitis suppurativa (HS) is characterized by recurrent, painful nodules in flexural areas. OBJECTIVE: The objective of this study was to explore the placebo response in HS randomized clinical trials and to compare it briefly with the placebo response in psoriasis and atopic dermatitis. METHODS: A Cochrane Review on interventions in HS was used as a starting point, and a systematic review was then undertaken by using the PubMed database, yielding 7 HS randomized clinical trials for inclusion in this study. RESULTS: This review demonstrates that there is a robust placebo response in HS that is most marked in physical signs but also marked in pain responses. LIMITATIONS: Multiple outcome measures utilized in these studies and reporting bias limited this review. CONCLUSION: This large placebo response has implications for clinical trial design. This knowledge can also help deliver improved clinical care by forming the basis of nonpharmacologic treatments and help optimize current medication use to maximize the placebo effect.
Authors: J M Oldhoff; U Darsow; T Werfel; K Katzer; A Wulf; J Laifaoui; D J Hijnen; S Plötz; E F Knol; A Kapp; C A F M Bruijnzeel-Koomen; J Ring; M S de Bruin-Weller Journal: Allergy Date: 2005-05 Impact factor: 13.146
Authors: Alexandra B Kimball; Murali Sundaram; Alan L Shields; Stacie Hudgens; Martin Okun; Catherine Foley; Arijit Ganguli Journal: J Am Acad Dermatol Date: 2018-05-19 Impact factor: 11.527
Authors: John W Frew; Caroline S Jiang; Neha Singh; David Grand; Kristina Navrazhina; Roger Vaughan; James G Krueger Journal: J Am Acad Dermatol Date: 2019-12-24 Impact factor: 11.527
Authors: John W Frew; Kristina Navrazhina; David Grand; Mary Sullivan-Whalen; Patricia Gilleaudeau; Sandra Garcet; Jonathan Ungar; James G Krueger Journal: J Am Acad Dermatol Date: 2020-05-13 Impact factor: 11.527